



Press release from Emotra AB (publ)

Göteborg, May 3, 2019

## Emotra is granted a patent in the USA

**The US will be one of Emotra's priority markets in the future. We have earlier announced that the Company has applied for patents in the EU, USA, Canada and Japan and patents have been granted in Sweden and Japan. The US patent office has now informed us that Emotra's American patent application "US Application No. 15/024,908" has been approved.**

The American patent office has informed Emotra that our patent application number 15/024,908, "A DEVICE FOR USE IN THE EVALUATION OF SUICIDE RISK", has been approved. The patent will be published on May 21, 2019, as U.S. Patent No. 10,292,636. Our patent application has already been approved by the Swedish Patent and Registration Office, PRV, for Sweden, and by the Japanese patent office. The company is still awaiting similar news from other patent offices, since they are still processing our applications.

### **Daniel Poté, our CEO, states**

*"The fact that the patent has now been approved in the US is of great importance to us. In fact, we have never really seen any significant objections to our patent applications from any patent office. Certain remarks from the US patent office gave us reason to make minor adjustments of our first patent requirement, and as a result the patent office has now approved the patent. At present, our focus is on getting started in a number of major European cities, but further on the USA, Japan and Canada will be important markets for our method."*

### **For further information about Emotra, please contact:**

Daniel Poté, CEO, telephone: +46-732 34 41 93, E-mail: [daniel@emotra.se](mailto:daniel@emotra.se)

*This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on May 3, 2019, under the above contact's supervision.*

---

**Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

Emotra AB (publ), Göteborgsvägen 88, SE-433 63 Sävedalen, Sweden

Tel: +46 73 234 41 93, [www.emotra.se](http://www.emotra.se)